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Abstract
In the US, mortality in sickle cell disease (SCD) increases after age 18-20 years.
Biomarkers of mortality risk can identify patients who need intensive follow-up and early
or novel interventions. We prospectively enrolled 510 SCD patients aged 3-20 years into
an observational study in 2006-2010 and followed 497 patients for a median of
88 months (range 1-105). We hypothesized that elevated pulmonary artery systolic pres-
sure as reflected in tricuspid regurgitation velocity (TRV) would be associated with mor-
tality. Estimated survival to 18 years was 99% and to 25 years, 94%. Causes of death
were known in seven of 10 patients: stroke in four (hemorrhagic two, infarctive one,
unspecified one), multiorgan failure one, parvovirus B19 infection one, sudden death
one. Baseline TRV ≥2.7 m/second (>2 SD above the mean in age-matched and gender-
matched non-SCD controls) was observed in 20.0% of patients who died vs 4.6% of
those who survived (P = .012 by the log rank test for equality of survival). The baseline
variable most strongly associated with an elevated TRV was a high hemolytic rate. Addi-
tional biomarkers associated with mortality were ferritin ≥2000 μg/L (observed in 60%
of patients who died vs 7.8% of survivors, P < .001), forced expiratory volume in 1 minute
to forced vital capacity ratio (FEV1/FVC) <0.80 (71.4% of patients who died vs 18.8% of
survivors, P < .001), and neutrophil count ≥10x109/L (30.0% of patients who died vs
7.9% of survivors, P = .018). In SCD children, adolescents and young adults, steady-state
elevations of TRV, ferritin and neutrophils and a low FEV1/FVC ratio may be biomarkers
associated with increased risk of death.
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1 | INTRODUCTION
Sickle cell disease (SCD) is one of the most common monogenic dis-
eases in the United States and worldwide. Characterized by the
homozygous Glu6Val mutation in HBB, the beta-globin gene, SCD is
associated with progressive multisystem organ damage and early
mortality. In recent decades, interventions such as newborn screening,
penicillin prophylaxis, immunizations, screening for risk of stroke with
transcranial Doppler, and disease-modifying therapies such as
hydroxyurea and chronic blood transfusion have led to a decline in
mortality and morbidity for children and adolescents with SCD, espe-
cially those living in developed countries.1 A Dallas, TX cohort study
of 711 newborns diagnosed with sickle cell anemia between 1983
and 2007 reported that 95% survived the first decade of life and that
the patterns of mortality are evolving.2 Mortality increases in adoles-
cents and young adults after transition to adult care had causes
including acute chest syndrome, multi-organ failure syndrome, sepsis
and other complications.3,4 Studies of SCD cohorts from Europe have
reported sepsis, stroke and acute anemia as the leading causes of
mortality in children with SCD.1,5-7
Despite advances in care, mortality in children, adolescents and
young adults with SCD in the US continues to be unacceptably high.
In one recent US study, mortality up to age 18 years was 6.1% in
patients with sickle cell anemia and 1.6% with milder forms of SCD.3
It is important to identify young patients at high risk of death so that
early interventions can be developed to reduce this high mortality.
The goal of the present analysis was to determine the frequency and
causes of death in a prospective, multi-institutional contemporary
cohort of children, adolescents and young adults with SCD and to
determine biomarkers associated with mortality in this cohort.
2 | METHODS
The Pulmonary Hypertension and the Hypoxic Response study
(PUSH) is a multi-institutional observational investigation that pro-
spectively followed a cohort of children, adolescents and young adults
with SCD. The study postulated that elevated systolic pulmonary
pressure as reflected in an elevated tricuspid regurgitation velocity
(TRV) would be a risk factor for mortality.
2.1 | Clinical evaluation of SCD patients and
controls
The study enrolled 510 patients with SCD and 75 control subjects
3 to 20 years of age from 2006 to 2010 at four institutions. The insti-
tutional review boards of all four participating institutions approved
the study protocol. The subjects and/or their parent or legal guardian
provided written informed consent to participate in accordance with
the Declaration of Helsinki. The trial is registered with clinicaltrial.gov
(NCT00495638). The controls were matched by age, sex and ethnicity
to approximately every sixth patient enrolled. SCD was confirmed by
hemoglobin electrophoresis, high performance liquid chromatography
or genetic analysis in some cases. The SCD patients were invited to
participate on a consecutive basis, as they presented for routine out-
patient care; no attempt was made to select them by known or per-
ceived risk factors. Before enrollment, at least 3 weeks had elapsed
since hospitalization, emergency department or clinic visit for a pain
crisis, acute chest syndrome, infection or other SCD related complica-
tion.8 Baseline clinical assessments including routine blood work,
echocardiography and pulmonary function testing were per-
formed.8-13 Standardized medical history forms that included ques-
tions regarding stroke, asthma and blood transfusions were filled out
by a clinical research nurse who interviewed the patient or a parent
and confirmed the findings by discussion with the patient's physician
and by chart review. At the time of enrollment in PUSH, it was the
policy of all participating institutions to perform transcranial Doppler
(TCD) screening on all eligible SCD patients. Follow-up for survival
was available for 497 of the participants at a median of 88 months
(range of 1-105 months) after enrollment.
2.2 | Definition of cutoff values for biomarkers
A TRV ≥2.7 m/second is more than 2 SD above the mean value in the
non-SCD controls in this study as described in the results section.
A serum ferritin of ≥2000 μg/L was used to define transfusional iron
overload in SCD patients by the Multi-Center Iron Overload Research
Group.14 A forced expiratory volume in 1 minute to forced vital capacity
ratio (FEV1/FVC) < 80% has been used to define pathological airway
obstruction in childhood asthma.15,16 An absolute neutrophil count
≥10 × 109 per liter is a cut-off that suggests the possibility of a bacterial
infection in otherwise healthy children and adolescents.17 N-terminal
pro-brain natriuretic peptide (NT-proBNP) ≥160 ng/L has been used to
define an elevated value in numerous previous studies.18-21 Hemoglobin
oxygen saturation ≤ 95% has been suggested to identify SCD children
at risk for hypoxia.22 Glomerular filtration rate (GFR) <90 mL/
minutes/1.73 m2 is the cutoff that defines Stage I decline in GFR by
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.23 Sys-
tolic blood pressure > 115 mmHg is the cut-off that requires further
evaluation or intervention in early adolescents.24 A left atrial
diameter ≥ 3.68 cm, a lateral transmitral Doppler early filling velocity to
tissue Doppler early diastolic mitral annular velocity (E/e0) ratio ≥ 8.84,
and a left ventricular internal diameter in diastole (LVIDD) z-score ≥ 1.8
are more than 2 SD above mean values in the non-SCD controls of this
study.
2.3 | Statistical analysis
We applied principal component analysis to create a hemolytic compo-
nent from age and site-adjusted values of aspartate amino transferase
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(AST), lactate dehydrogenase (LDH), total bilirubin and reticulocyte
count. Statistical comparisons were made using the Fisher exact test for
categorical variables and the Student t test for continuous variables (with
normally transformed data). The independent relationship of serum ferri-
tin concentration with baseline variables was assessed with multiple lin-
ear regression. The survival of patients over the study period was
calculated by Kaplan-Meier estimate. The association of historical vari-
ables and biomarkers with mortality was determined by the log rank test
for equality of survivor function. We did not perform multi-variate analy-
sis of mortality using the identified risk factors because there were too
few deaths to justify this approach. Analyses were performed in Stata
15.0 (StataCorp, College Station, TX).
3 | RESULTS
3.1 | Comparison of SCD patients and controls
The genotypes of the 497 SCD patients with follow-up information
were HbSS in 372 (74.8%), HbSC in 91 (18.4%), Hb Sβ+-thalassemia in
TABLE 1 Clinical characteristics of SCD patients and controls. Results expressed in median and interquartile range unless otherwise
indicated. Statistical comparison by t test or Fisher's exact test
N SCD N Controls P
Demographics and genetics
Age (years) 497 12 (7-16) 75 14 (9-17) .021
Female gender in no. (%) 497 243 (48.9%) 75 40 (53.3%) .5
Alpha-thalassemia in no. (%)













Asthma 493 119 (24.1%) 75 14 (18.7%) .38
Stroke 492 52 (10.6%) 75 0 .001
Acute chest syndrome or pneumonia 492 239 (48.6%) 75 2 (2.7%) <.001
Physical examination
Body mass index (kg/m2) 494 17.8 (15.7-21.5) 74 21.3 (17.8-24.3) <.0001
Systolic blood pressure (mmHg) 480 112 (104-119) 73 116 (109-125) .001
Diastolic blood pressure (mmHg) 480 64 (59-71) 73 68 (62-75) .008
Echocardiogram and PFT
Tricuspid regurgitation velocity (m/sec) 441 2.3 (2.1-2.5) 67 2.1 (2.0-2.3) <.0001
Left ventricular internal diameter z score 469 1.3 (0.2-2.2) 71 −0.5 (−1.3-0.1) <.0001
Left atrial diameter (cm) 477 2.9 (2.5-3.3) 73 2.7 (2.4-3.0) .002
Lateral E/e0 476 6.4 (5.5-7.4) 73 6.1 (5.4-7.0) .036
FEV1/FVC (%) 156 84 (80-89) 34 85 (83-90) .30
Laboratory tests
Oxygen saturation (%) 472 98 (97-99) 71 99 (99-100) <.0001
eGFR (Schwartz)* (mL/min/1.73 m2) 475 135 (111-165) 73 95 (80-110) <.0001
Absolute neutrophils (109 per L) 478 4.5 (3.3-6.8) 74 2.7 (2.0-3.7) <.001
Hemoglobin (g/L) 480 91 (80-104) 75 126 (121-138) <.0001
Reticulocytes (%) 463 7.6 (4.0-11.6) 63 1.0 (0.8-1-1.4) <.0001
Ferritin (μg/L) 420 178 (85-620) 70 43 (28-62) <.0001
Alanine aminotransferase (U/L) 492 31 (18-42) 75 22 (14-34) .0005
Asparate aminotransferase(U/L) 480 42 (31-54) 75 21 (17-29) <.0001
Total bilirubin (μmol/L) 480 37.6 (23.9-56.4) 75 8.6 (5.1-12.0) <.0001
Lactate dehydrogenase (U/L) 437 398 (287-561) 73 180 (152-209) <.0001
NT-proBNP (ng/L) 456 85 (47-155) 68 36 (20-48) <.0001
Abbreviations: FEV1/FVC, forced expiratory volume in 1 minute to forced vital capacity ratio.
*eGFR (estimated glomerular filtration rate) = 0.413 × (height in cm/creatinine in mg/dL).
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18 (3.6%), Hb Sβ0-thalassemia in 9 (1.8%), and other genotypes includ-
ing Hb SDLos Angeles and Hb SOArab in 7 (1.4%). The SCD patients and
control subjects are compared in Table 1. The BMI, systemic blood
pressure, and oxygen saturation were lower in the SCD patients, while
TRV and LVIDD z score were higher. Among laboratory tests,
creatinine and hemoglobin were lower in the SCD patients while
neutrophils, reticulocytes, ferritin, AST, total bilirubin, LDH and
NT-proBNP were higher. Twenty four percent of SCD patients vs
19% of healthy non-SCD controls had a history of asthma. Blood
eosinophil counts were significantly higher in subjects with history of
asthma (mean 0.43 × 109 per liter vs 0.32 × 109 per liter, P = .022)
and, in the subgroup of participants with pulmonary function tests
(N = 190), FEV1/FVC was significantly lower in subjects with history
of asthma (median 0.82 vs 0.86, P < .001).
3.2 | Definition of elevated TRV in SCD patients
Most studies of children and adolescents with SCD have defined an
elevated TRV to be ≥2.5 m/second,25-29 but this cut-off represents
2 SD above the mean value in adult rather than pediatric non-SCD
controls.30 For the present study, we performed echocardiograpy in
75 control children without SCD, 67 of whom had a measurable TRV.
The control children and adolescents were studied during the same
time period as the SCD subjects and TRV was determined using the
same equipment and by the same investigators. As previously publi-
shed in a subgroup of the PUSH study,8 we used TRV values greater
than 2 SD above the mean in the control subjects to define elevated
TRV in patients with SCD. The mean ± 2 SD TRV in the control sub-
jects was 2.1 ± 0.5 m/second. Therefore, we defined elevated TRV to
be ≥2.7 m/second. Twenty-three (4.9%) of the SCD subjects had an
elevated TRV at baseline using this definition.
3.3 | Serum ferritin in SCD patients
The serum ferritin concentration in SCD patients ranged from
7-12,700 ng/mL. In linear regression analysis of serum ferritin in the
F IGURE 1 Kaplan–Meier estimated survival by age of follow-up
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PUSH data set, transfusion history, absolute granulocyte count and
the liver function test, ALT, accounted for 56% of the variation in
serum ferritin. Transfusion history reflecting the iron burden of trans-
fused red blood cells had the strongest independent relationship with
higher serum ferritin concentration (partial r = 0.61, p < 0.000001).
Higher absolute granulocyte count reflecting inflammation (partial r =
0.17, p = 0.000006) and higher ALT reflecting hepatocellular dysfunc-
tion (partial r = 0.11, p = 0.003) also had significant independent rela-
tionships with serum ferritin concentration.
3.4 | Estimated survival and causes of death in
SCD patients
Hydroxyurea was prescribed for 36.7% of the SCD subjects at base-
line and 14.3% were on a chronic transfusion program. The mean cor-
puscular volume (median 92 fL vs 81 fL; P < .001) was significantly
greater and the absolute neutrophil count (median 4.2 × 10/L vs
4.8 × 109/L; P = .03) was significantly lower in patients receiving
hydroxyurea, suggesting compliance with the regimen at baseline.
A history of stroke was obtained in 52 patients with a median age of
16 years (range 4-20 years); 29 (55.8%) were on a chronic transfusion
program and 21 (40.4%) were on hydroxyurea therapy. This history of
stroke seems high compared to the Dallas newborn cohort2 and the
Cooperative Study of Sickle Cell Disease Cohort,31 possibly reflecting
that our study was conducted at tertiary care centers where patients
with special management needs are referred. There was a history of
recurrent acute chest syndrome in 73 of the patients, 41 (56.2%) of
whom were treated with hydroxyurea at baseline.
The median follow up was 88 months (interquartile range
78-95 months). Ten of 497 patients (2.0%) died during the follow-up
period. Eight had hemoglobin SS and two had hemoglobin SC. The
median age at the time of death was 21 years (range 16-28 years).
The overall survival at 18 years of age was 99% (95%CI: 98%-99%)
TABLE 3 Relationship of baseline medical history with death. P values were calculated from log rank test for equality of survival
N Alive N Died P (log rank test)
Chronic transfusion program, no. (%) 479 64 (13.4%) 10 6 (60.0%) <.001a
History of stroke, no. (%) 482 47 (9.8%) 10 5 (50.0%) .001a
Age ≥ 13 years, no. (%) 487 227 (46.6%) 10 9 (90.0%) .008a
History of asthma, no (%) 483 113 (23.4%) 10 6 (60.0%) .009a
3+ Severe pain episodes past year, no. (%) 487 91 (18.6%) 10 5 (50.0%) .013a
α-thalassemia gene deletion, no. (%) 459 147 (32.0%) 9 5 (55.6%) .09
History of ACS or pneumonia, no (%) 482 232 (48.1%) 10 7 (70.0%) .17
Hemoglobin SS genotype, no (%) 487 364 (74.7%) 10 8 (80.0%) .70
Male gender, no (%) 487 248 (50.9%) 10 6 (60.0%) .64
Hydroxyurea treatment, no (%) 483 177 (36.6%) 10 4 (40.0%) .88
aSignificant after adjusting for multiple hypothesis testing using False Discovery Rate < 0.05.
TABLE 4 Relationship of baseline TRV and other biomarkers with death. P values were calculated from log rank test for equality of survival
N Alive N Died P (log rank test)
TRV ≥2.7 m/sec, no. (%) 462 21 (4.6%) 10 2 (20.0%) .012a
Ferritin ≥2000 μg/L, no. (%) 410 32 (7.8%) 10 6 (60.0%) <.001a
FEV1/FVC < 0.80, no (%) 149 28 (18.8%) 7 5 (71.4%) <.001a
Absolute neutrophils ≥10 × 109 per L, no. (%) 468 37 (7.9%) 10 3 (30.0%) .018a
NT-proBNP ≥160 (ng/L), no (%) 446 103 (23.1%) 10 5 (50.0%) .044
eGFR (Schwartz) ≤ 90 mL/min/1.73 m2 465 33 (7.1%) 10 2 (20.0%) .08
Oxygen Saturation ≤ 95%, no (%) 462 67 (14.5%) 10 3 (30.0%) .24
Systolic blood pressure > 115 mm Hg, no. (%) 470 165 (35.1%) 10 4 (40%) .72
Hemolytic component* over the mean, no. (%) 403 206 (51.1%) 10 5 (50%) .83
Left atrial diameter ≥ 3.68 cm, no. (%) 457 52 (11.4%) 10 0 (0%) .23
Lateral E/e0 ,≥8.84 no. (%) 454 36 (7.9%) 10 0 (0%) .37
LVIDD z score ≥ 1.8, no. (%) 459 170 (37.0%) 10 3 (30.0%) .60
Abbreviations: eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal-prohormone B-type natriuretic peptide; TRV, Tricuspid regurgitation
velocity.
aSignificant after adjusting for multiple hypothesis testing using False Discovery Rate < 0.05.
bPrincipal component 1 of reticulocyte count, LDH, AST and total bilirubin.
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and at age 25 years was 94% (95%CI: 87%-97%) (Figure 1). The base-
line age, age of death and cause of death in the 10 patients who died
are summarized in Table 2. The causes of death in the hemoglobin SS
patients were de novo stroke in one, recurrent stroke in three, multi-
organ failure in one and unknown in three. The causes of death in the
hemoglobin SC patients were parvovirus B19 infection in one and
sudden death at home in one. Seven of the patients who eventually
died were on a chronic transfusion program and/or received treat-
ment with hydroxyurea at the time of enrollment.
3.5 | Relationship of baseline medical history to
death in SCD patients
The prevalence of baseline medical history variables according to
death status are shown in Table 3. Older age, a chronic transfusion
program, a history of stroke, a history of asthma and 3+ severe pain
episodes in the past year were the strongest baseline medical history
variables associated with increased risk of death. As expected there
was a high degree of overlap among patients on a chronic transfusion
program and those with a history of stroke: 41.7% of the patients on
a chronic transfusion program had a history of stroke vs 5.6% of those
not on such a program. Hemoglobin SS genotype and baseline
hydroxyurea treatment status were not significantly associated with
mortality in this cohort.
3.6 | Relationship of baseline TRV to risk of death
in SCD patients
Baseline TRV ≥2.7 m/second was observed in 20.0% of the patients
who died vs 4.6% of survivors (P = 0.012 by the log rank test for
equality of survival) (Table 4). Death occurred in two (8.7%) of
23 patients with TRV ≥2.7 m/second compared to eight (1.8%) of
449 patients with lower TRV values.
3.7 | Relationship of other biomarkers with death
in SCD patients
Additional biomarkers associated with mortality were ferritin
≥2000 μg/L, FEV1/FVC <0.80 and absolute neutrophil count
≥10 × 109 per L (Table 4). Death occurred in six (15.8%) of 38 patients
with ferritin ≥2000 μg/L vs four (1.1%) of 382 patients with lower fer-
ritin values (P < .001 by the log rank test for survival). The FEV1/FVC
ratio was determined in a subset of 156 patients. Death occurred in
5 (15.2%) of 33 patients with FEV1/FVC <0.80 vs five (4.1%) of
123 patients with higher FEV1/FVC values (P < .001). Death occurred
in three (7.5%) of 40 patients with absolute neutrophil count
≥10 × 109/L vs seven (1.6%) of 428 patients with lower neutrophil
counts (P = .018). Left atrial diameter, lateral E/e0, LVIDD z-score,
NT-proBNP and a hemolytic component were not significantly associ-
ated with mortality in these analyses.
3.8 | Relationship of baseline variables with the
prognostic biomarker categories
The strongest association of TRV ≥2.70 m/second was with a high
degree of hemolysis as shown by the hemolytic component (P < .001).
The strongest associations of ferritin ≥2000 μg/L were with older age,
a chronic transfusion program, a history of stroke, and an elevated
neutrophil count (P < .001). FEV/FVC < 0.8 was associated with a his-
tory of asthma (P < .001) and a higher eosinophil count (P = .006). The
strongest associations of neutrophil ≥10 × 109/L were with a higher
degree of hemolysis as reflected in the hemolytic component, an ele-
vated serum ferritin, and a chronic transfusion program (P < .001).
4 | DISCUSSION
In this report we describe certain biomarkers associated with mortal-
ity, predominantly after transition to adulthood, in a cohort of chil-
dren, adolescents and young adults with SCD who were followed
prospectively in the Pulmonary Hypertension and the Hypoxic
Response in SCD (PUSH) study. Stroke was the cause of death in four
of 10 cases and in four of seven in whom the cause of death was
known. There was a history of previous stroke in three of the four
who died of stroke. Three of the four patients who died of stroke
were on a chronic transfusion program and two of the three with a
past history of stroke were on a chronic transfusion program. Baseline
historical variables that were significantly associated with death over
a median of almost 7 years of observation of this cohort included a
chronic blood transfusion program, a history of stroke, older age, and
histories of asthma and three or more severe pain episodes in the
past year.
In the PUSH cohort we were particularly interested in biomarkers
of mortality, with a focus on the TRV. The echocardiograpy-
determined TRV is considered to be a valid estimate for the systolic
pulmonary artery pressure.32,33 An elevated TRV can reflect pulmo-
nary arterial hypertension or an increased pulmonary wedge pressure
secondary to pulmonary venous hypertension or cardiac diastolic dys-
function as reflected in the echocardiogram parameters, left atrial
diameter and the lateral E/e0 ratio.34 The TRV, left atrial diameter and
lateral E/e0 were all increased in the SCD patients in this study, as
shown in Table 1. A number of studies have defined an elevated TRV
to be values ≥2.5 m/second, which is more than 2 SD above the mean
in non-SCD adult controls, and have reported that an elevated TRV by
this definition is associated with increased mortality in SCD
adults.30,35-37 Some studies have found that a higher TRV cut-off of
3.0 m/second is more strongly associated with mortality than
the 2.5 m/second cut-off.38,39 The definition of elevated TRV of
≥2.5 m/second has been adopted for studying children with SCD,25-29
although it is not clear that the same definition of elevated TRV would
apply to both adults and children. The PUSH study enrolled a
non-SCD control group contemporaneous with the SCD patients, and
we utilized this control group to define an elevated TRV to be
≥2.7 m/second, or more than 2 SD above the mean in non-SCD
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controls. The TRV values in this range were found in 4.9% of the SCD
patients and proved to be significantly associated with death. An ele-
vated hemolytic rate was the strongest baseline variable associated
with TRV ≥2.70 m/second in the present study. Left atrial diameter
and lateral E/e0 did not have significant positive associations with TRV
≥2.70 m/second.
Three additional biomarkers measured at baseline proved to be
even more significantly associated with mortality, namely serum ferri-
tin ≥2000 μg/L (found in 9.1% of the patients), FEV1/FVC <0.8 (found
in 21.2% of the patients), and absolute neutrophils ≥109/L (found in
8.4% of the patients). The serum ferritin was ≥300 μg/L, the upper
limit of the reference range in adults, in 38.8% of the SCD patients in
this study and it was ≥2000 μg/L in 9.1% of them. Serum ferritin is an
indirect indicator of iron stores40 that increases in relation to the
amount of blood transfused in sickle cell disease and other condi-
tions.41-43 Serum ferritin also increases with inflammation or with
hepatocellular damage in the absence of increased iron stores.44 In
sickle cell anemia patients that elevated serum ferritin concentration
reflects increased iron stores because of the frequency of blood trans-
fusions for non-blood loss indications.41 In the present study, 71% of
subjects with ferritin ≥2000 μg/L were on a chronic transfusion pro-
gram while 10% of subjects with a lower serum ferritin were on such
a program. Overall in the PUSH cohort, serum ferritin appears to be a
composite marker that reflects increased iron stores related to blood
transfusions, the presence of inflammation (independent relationship
with absolute neutrophil count), and the potential organ toxicity of
iron overload (independent relationship with increased ALT).
Low FEV1/FVC is a marker of airway obstruction that affects
about one in five children with SCD.13,45 Reduction in lung growth,46
higher hemolysis13 and/or anemia,47 and increased pulmonary capil-
lary blood volume48 may contribute to airway obstruction in SCD chil-
dren. A history of asthma and higher blood eosinophil counts were
associated with a low FEV1/FVC ratio in the present study, consistent
with a potential allergic component as well. Our present observation
of a relationship between low FEV1/FVC ratio and death is in contrast
to another recent study,45 but is consistent with reports that mea-
sures of lower airway obstruction are associated with more frequent
hospitalizations for pain or acute chest syndrome in children with
SCD49 and with higher mortality in adults with SCD.35
In SCD, intravascular hemolysis, free heme, inflammation and
ischemia-reperfusion injury accelerate neutrophil activation and bind-
ing to red bloods, platelets and endothelium.50-52 Neutrophil activa-
tion is believed to play an important role in vaso-occlusive crisis.53 In
our study, a neutrophil count ≥10 × 109L was a significant prognostic
factor of mortality, and markers of hemolysis and iron overload were
associated with higher neutrophil count.
Hydroxyurea use at baseline was not significantly different
between the patients who died and survived in the PUSH study.
Although lower neutrophil count and higher mean corpuscular volume
suggested compliance with hydroxyurea at baseline, we did not
evaluate adherence to hydroxyurea therapy during the study. Other lim-
itations are that only one TRV measurement was made at inclusion into
the study, that the cohort was recruited starting at age 3 years and the
mortality rate reflects this characteristic of the study, that the exact
cause of death was not known for all of the subjects who died, and that
we did not focus on certain potential risk factors for mortality, such as a
past history of splenic sequestration and hypercoagulation. It would
have been ideal to follow the PUSH cohort for a longer period of time
but we were unable to secure funding to do so.
In summary, the estimated survival of the PUSH cohort of chil-
dren, adolescents and young adults with SCD was 99% to 18 years
and this declined to 94% at 25 years. Stroke was the most common
cause of death. Elevated systolic pulmonary artery pressure as
reflected in TRV ≥2.7 m/second, high serum ferritin concentration,
low FEV1/FVC and high neutrophil count were biomarkers of
increased risk of death, predominantly after transition to adulthood.
These biomarkers are easily obtainable and potentially can help iden-
tify patients in need of novel new therapies as well as established
approaches such as the use of hydroxyurea to prevent vaso-occlusive
complications, the need for blood transfusions and the use of iron
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